Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data ...
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...
Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127 NX-2127 degrades BTK in patients regardless of ...
Ascentage Pharma receives US FDA’s IND clearance for BTK degrader APG-3288 to treat patients with relapsed/refractory B-cell malignancies: Rockville, Maryland Friday, January 9, ...
Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL). The ...
Covalent Bruton tyrosine kinase inhibitors (BTKis) have improved CLL management, but discontinuation due to adverse events and disease progression remains a challenge. Sequential BCL2 inhibitor ...
New research from Memorial Sloan Kettering Cancer Center (MSK) investigates overcoming drug resistance in chronic lymphocytic leukemia; describes a new method for identifying driver mutations in tumor ...
STOCKHOLM — Approximately half of patients with chronic lymphocytic leukemia (CLL) who relapse after treatment with ibrutinib (Imbruvica, Pharmacyclics) show acquired mutations in the Bruton's ...
DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2% DZD6008, a BBB-penetrant 4 th ...
Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback